Esperion Therapeutics surges on Archimed's $1.1 bln go-private deal

Esperion Therapeutics

01/05/2026 12:53

** Shares of drugmaker Esperion Therapeutics ESPR.O up 58.4% at $3.17 premarket

** Investment firm Archimed to take co private for up to $1.1 billion

** ESPR shareholders will receive $3.16 in cash for each share, representing a premium of about 58% to co's last close

** Firms said that shareholders could also receive additional contingent payments totaling up to $100 million if ESPR meets certain sales targets in the coming years

** The deal is expected to close in the third quarter of 2026

** Till Thursday's close, ESPR stood at a market capitalization of about $514.81 mln, with 257.40 mln shares outstanding - LSEG data

** As of last close, ESPR stock down 45.9% YTD

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))